Bristol-Myers Squibb Co (LTS:0R1F)
$ 59.4 -0.61 (-1.02%) Market Cap: 119.70 Bil Enterprise Value: 163.01 Bil PE Ratio: 0 PB Ratio: 6.98 GF Score: 82/100

Bristol-Myers Squibb Co at Guggenheim Partners Healthcare Talks Oncology Days Transcript

Feb 12, 2021 / 05:00PM GMT
Release Date Price: $59.97 (-0.11%)
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

Thanks, everybody. Good afternoon. Thanks for joining us for a fireside chat session with Bristol-Myers Squibb. I'm Seamus Fernandez, Guggenheim's global biopharma analyst. We're joined today by Chris Boerner, Chief Commercialization Officer of Bristol-Myers Squibb. And obviously, we have a brief (inaudible) time here. I do apologize we're starting a touch late just because my Internet connection was unstable. So we're using the support of the global network at this point. So...

Christopher S. Boerner
Bristol-Myers Squibb Company - Executive VP & Chief Commercialization Officer

Welcome to the world we live in.

Questions & Answers

Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

Exactly. So thanks again, everybody, for joining us. We do have a short time. So Bristol's breadth in oncology is obviously quite

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot